ProMIS Neurosciences Inc PMN

acu193 question

[M101]

I think I opined last year that the acu193 story had a hole in it for Promis investors: it entirely ignores the role of misfolding.  This seems relevant now that their stock price is down huge, but I'm not sure there's actually a connection as their P1 schedule has been pushed back.

So the question is, am I mssing something with Acumen or is their hypothesis simply that all ABOs are bad, so while some mers are worse than others it's safe tp target them all?   I feel like I must have it wrong because that logic doesn't explain AD progression, leaving it to cascade effects with presumably other individually variable triggers. 

With Promis and Acumen now on very similar time lines through P1 the market will be looking for differentiation, but neither company will whizz on the other's parade so what will be the strategy? .

[bball67]

Just did a quick review of Acumen. IPO priced at $16 and sold for over $20 first day, now $3.30. First quarter conference call, pushed back phase 1 trial of 62 patients to by end of first half of 2023. Can't believe the low number of patients. Market cap is now $133M or three times Promis market cap. I suggest anyone wanting to compare the two companies, to read the first quarter Acumen

[M101]

Thanks for the opinion. This is why it's now trading at less than cash on hand, but how it got to its ridiculous opening valuation and what Promis' promotional strategy is when the inevitable comparisons are made is what makes it relevant here now.   There will be some like Farmer who focus on the price decay rather than the pre-market manipulation when really it's two sides of

[FarmerBetty]

You got to love it ,remove Acumen from today's Corporate update with how many repeat slides. What about Eugene and Elliott removing last years Acumens comments what weak leadership. 

[M101]

Was there a mention of Acumen in a prior corporate update? I know ACU193 appears in a paper by Cashman & Plotkin, but it wouldn't fit well in a table comparing P2-3 drugs to demonstrate the need for oligomer selectivity, it needs to fail first. I like the direction of evololution of this document. I'd like to see a summary of P1 level competion framed in the context of next generation